CD8+ T Cell Exhaustion in Cancer
JS Dolina, N Van Braeckel-Budimir… - Frontiers in …, 2021 - frontiersin.org
A paradigm shift in the understanding of the exhausted CD8+ T cell (Tex) lineage is
underway. Originally thought to be a uniform population that progressively loses effector …
underway. Originally thought to be a uniform population that progressively loses effector …
[HTML][HTML] Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive
intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor …
intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor …
Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 …
X Zhang, Z Wei, T Yong, S Li, N Bie, J Li, X Li… - Nature …, 2023 - nature.com
The durable response rate to immune checkpoint blockade such as anti-programmed cell
death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly …
death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly …
Tumor‐microenvironment‐activatable polymer nano‐immunomodulator for precision cancer photoimmunotherapy
Cancer nanomedicine combined with immunotherapy has become a promising strategy for
treating cancer in terms of safety and potency; however, precise regulation of the activation …
treating cancer in terms of safety and potency; however, precise regulation of the activation …
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models
M Datta, S Chatterjee, EM Perez… - Proceedings of the …, 2023 - National Acad Sciences
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma trials. Here, we
found that ICBs induce cerebral edema in some patients and mice with glioblastoma …
found that ICBs induce cerebral edema in some patients and mice with glioblastoma …
PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer
X Zhou, D Fang, H Liu, X Ou, C Zhang, Z Zhao, S Zhao… - Cancer letters, 2022 - Elsevier
Myeloid-derived suppressor cells (MDSCs) accumulation in multiple tumor is associated
with immune checkpoint inhibitors (ICIs) resistance. However, mechanisms of MDSCs in ICIs …
with immune checkpoint inhibitors (ICIs) resistance. However, mechanisms of MDSCs in ICIs …
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Y Tie, F Tang, Y Wei, X Wei - Journal of hematology & oncology, 2022 - Springer
Immunotherapies like the adoptive transfer of gene-engineered T cells and immune
checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some …
checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some …
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
S Seitz, TF Dreyer, C Stange, K Steiger… - British Journal of …, 2022 - nature.com
Background Response to immune checkpoint blockade (ICB) in ovarian cancer remains
disappointing. Several studies have identified the chemokine CXCL9 as a robust …
disappointing. Several studies have identified the chemokine CXCL9 as a robust …
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice
The biological determinants of the response to immune checkpoint blockade (ICB) in cancer
remain incompletely understood. Little is known about dynamic biological events that …
remain incompletely understood. Little is known about dynamic biological events that …
Injectable cold atmospheric plasma-activated immunotherapeutic hydrogel for enhanced cancer treatment
T Fang, X Cao, B Shen, Z Chen, G Chen - Biomaterials, 2023 - Elsevier
Despite the promise of immune checkpoint blockade (ICB) for cancer treatment, challenges
associated with this therapy still exist, including low response rates and severe side effects …
associated with this therapy still exist, including low response rates and severe side effects …